MedTrace Logo

TruGraf® Testing in High-Risk Kidney Transplant Recipients

NCT04266613 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2021-09-01

No results posted yet for this study

Summary

This is an observational study to evaluate TruGraf® testing in high immune risk kidney transplant recipients. TruGraf is the first and only non-invasive test approved by Medicare to rule out silent rejection in stable kidney transplant recipients.

Conditions

  • Kidney Transplant Rejection

Interventions

DIAGNOSTIC_TEST

TruGraf® Testing

5 mL collection PAXgene blood sample

Sponsors & Collaborators

  • The Methodist Hospital Research Institute

    collaborator OTHER

  • Transplant Genomics, Inc.

    lead INDUSTRY

Principal Investigators

  • John Holman, MD · Transplant Genomics, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-20
Primary Completion
2021-06-23
Completion
2021-06-23

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04266613 on ClinicalTrials.gov